Join Here   |   Log In

Homocysteine: Genetics, High Homocysteine Levels, and Solutions

Key takeaways:

  • Homocysteine is produced from methionine in the methionine cycle and can either be remethylated back to methionine or converted through the transsulfuration pathway into cysteine and glutathione.
  • High homocysteine can cause oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum stress.
  • Both homocysteine and its reactive metabolite homocysteine thiolactone can damage blood vessels and other tissues, and even levels in the upper “normal” range are associated with increased all‑cause mortality
  • Genetic variants can increase the risk of high homocysteine, depending on your intake of B vitamins and choline. Lifestyle factors and the gut microbiome can also play a role.
Preview your genes:

This article is free and open to everyone as a sample of what a full Genetic Lifehacks article offers!

Members: Be sure you are logged in to see your genotype data below.

What is homocysteine?

Homocysteine is a sulfur-containing amino acid that is a byproduct of the metabolism of methionine.

What’s methionine? Methionine is an essential amino acid that we get from protein-rich foods. Essential means that it is an amino acid that we have to get from foods, and it is needed for the production of proteins in the body.

Methionine is used by cells to supply methyl groups, which are required in many different cellular reactions. In the methionine cycle, methionine receives adenosine from ATP, which then creates SAM-e (s-adenosyl-methionine). SAM-e can then transfer a methyl group for methylation reactions. When SAM-e loses a methyl group, it becomes SAH (s-adenosyl-homocysteine), which then is hydrolyzed to form homocysteine.[ref]

Homocysteine can then be converted back to methionine or transformed in other pathways.

When any of these pathways are blocked, homocysteine levels can rise, which causes negative long-term health effects.

Homocysteine at a glance
Aspect Key points
What it is Sulfur-containing amino acid formed from methionine via SAMe → SAH → homocysteine in the methionine cycle.​
Why it matters Excess homocysteine drives oxidative stress, ER stress, protein misfolding, mitochondrial dysfunction, and endothelial damage.​
Main fates Remethylation to methionine (folate/B12 or betaine/BHMT), transsulfuration to cysteine/glutathione (B6/CBS), or conversion to homocysteine thiolactone.​
High-hcy risks CVD, stroke, metabolic syndrome, NAFLD, type 2 diabetes, osteoporosis, brain atrophy/Alzheimer’s, depression, pregnancy complications.​
Lab cutoffs Normal ~5–13/15 μmol/L; high >15 μmol/L ; low <5 μmol/L.​

How are homocysteine levels maintained?

Homocysteine is constantly being formed and converted. These are ongoing cycles that are constantly happening in your cells, and homocysteine levels are regulated by the cells to maintain a fairly consistent level.

The level of homocysteine depends on the amount that is formed in the conversion of SAMe and SAH (S-adenosyl homocysteine) and the amount that is recycled or further broken down.

In cells, homocysteine is metabolized in three ways:[ref]

  1. It can be remethylated to form methionine (requires folate, 🧬MTHFR, and vitamin B12, 🧬 MTR- or needs betaine, 🧬BHMT and PEMT genes)
  2. Can be converted to cysteine (🧬 CBS gene, serine and B6 as a cofactor), which is used in the synthesis of glutathione
  3. It can be converted to homocysteine thiolactone, which can be a problem at higher levels

 

Let’s dig into each of these pathways further:

Methionine Cycle: Homocysteine, Methionine, SAMe, and SAH

Homocysteine is maintained at a relatively constant level by several mechanisms in the methionine cycle.

Most homocysteine is remethylated to methionine using methyl groups from the folate cycle or donated from trimethylglycine (also called betaine). This process occurs primarily in the liver and requires methylfolate along with vitamin B12.

When SAH is high, methylation reactions are decreased, reducing the conversion of methionine to SAMe and methyl groups.  When SAMe is low, the remethylation of homocysteine to methionine is prioritized in the cell (instead of the transsulfuration pathway).[ref]

Drains on methyl groups:
About 40% of methyl groups are used for creatine synthesis, so when creatine levels are higher, it can reduce the need for methyl groups. Another major use of methyl groups in the body is for the synthesis of phosphatidylcholine from choline, so when phosphatidylcholine levels are higher, there is less of a strain on the methylation cycle.[ref]

Where is homocysteine produced?
Homocysteine is primarily produced in the liver, but the intestines, kidneys, skeletal muscle, and pancreas can also produce minor amounts of homocysteine. This makes liver health important in maintaining normal homocysteine levels. [ref][ref][ref]

Homocysteine goes down the transsulfuration pathway to form cysteine:

Another path that homocysteine can take is to be converted to cysteine through a two-step process in the transsulfuration pathway. This occurs primarily in the liver and kidneys. Vitamin B6 is required as a cofactor, and serine is also used. The 🧬 CBS enzyme catalyzes the reaction.

Related article: CBS gene and sulfur

Cysteine is a sulfur-containing amino acid that can be converted to taurine or sulfates, including glutathione.  Glutathione is an antioxidant used in cells to counteract oxidative stress.

The flux of cysteine and the end products are driven by how much methionine is eaten, as well as how much glutathione is needed to combat oxidative stress in cells.[ref][ref]

Simplified overview of Hcy (Homocysteine) cycling through the methionine cycle or going down the transsulfuration pathway to cysteine. CC PMC6412520

 

Homocysteine thiolactone: Damaging endothelial cells, increasing inflammation

Homocysteine can also become homocysteine thiolactone when a thiol group is attached. While the methylation cycle gets a lot of press, the metabolism of homocysteine-thiolactone is also really important.

Homocysteine thiolactone can cause damage to some types of cells, particularly the endothelial cells that line blood vessels. Therefore, the body has ways to get rid of homocysteine-thiolactone quickly.

Most homocysteine thiolactone is eliminated through the kidneys, so good kidney function is important.

PON1, an enzyme that circulates in the blood attached to HDL cholesterol, metabolizes homocysteine-thiolactone back to homocysteine in the bloodstream. 🧬 PON1 levels vary widely among individuals, in part due to genetic variants in PON1. Some of the negative effects of high homocysteine levels are modulated by the PON1 genotype.[ref] BLMH and BPHL are additional enzymes that can also metabolize homocysteine-thiolactone.[ref]

Higher levels of homocysteine-thiolactone are also found in chronic inflammatory conditions, such as rheumatoid arthritis, inflammatory eye disease, and AMD.[ref][ref][ref]

Recap: Homocysteine metabolic pathways
Pathway Key enzymes & cofactors Main products Clinical relevance
Remethylation (folate/B12) MTHFR → methylfolate; MTR uses methyl-B12.​ Methionine, SAMe restored.​ Folate/B12 deficiency or MTHFR/MTR variants raise homocysteine.
Remethylation (betaine/BHMT) BHMT uses betaine from choline.​ Methionine regenerated, less reliance on folate.​ Important backup when folate/B12 are low; influenced by BHMT and PEMT variants.
Transsulfuration CBS (B6-dependent) and downstream enzymes.​ Cysteine → glutathione, taurine, sulfates.​ Supports antioxidant defense; CBS defects can cause severe hyperhomocysteinemia.
Thiolactone formation Mis-activation by tRNA synthetase; detox via PON1, BLMH, BPHL.​ Homocysteine thiolactone → back to homocysteine or excreted.​ Excess thiolactone damages endothelium, promotes inflammation and thrombosis.

 

Let’s take a look at why high homocysteine levels cause problems in the body, and then we’ll look at genetic variants in the above cycles that can affect homocysteine levels when combined with dietary choices.

Why is high homocysteine a problem?

Recent research explains how and why high homocysteine levels cause adverse effects on the cardiovascular system, the brain, inflammation, the pancreas, and overall health.

Post-translational protein modifications:

Recent research shows that homocysteine can bind to proteins after they are synthesized in post-translational protein modification. Proteins are made up of amino acids that are arranged in a specific way. The incorporation of homocysteine (an amino acid) ultimately changes the structure of the protein and can affect its function.

For example, higher levels of homocysteine mean that certain proteins important in cardiovascular disease and neurodegenerative diseases can end up with a homocysteine attached or incorporated into them.[ref]

The process of post-translational protein modification happens all the time and in a number of different ways, including the addition of other amino acids, sugar molecules, or fatty acids.

The problem arises when too much homocysteine is available, and it ends up being incorporated into too many proteins. For example, homocysteine may take the place of methionine in proteins. The addition of homocysteine causes some proteins to become pro-inflammatory or pro-thrombotic.[ref]

Oxidative stress, ER stress, and mitochondrial dysfunction:

High homocysteine levels are also associated with increased oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress.

Animal studies show that increasing methionine in the diet slightly increases homocysteine levels. This slight increase then leads to an increase in inflammatory cytokines (TNF-alpha, IL-1 beta) in macrophages[ref]

Endoplasmic Reticulum (ER) stress, protein misfolding:
The endoplasmic reticulum (ER) is an organelle in cells where newly synthesized proteins are folded, lipids are synthesized, and calcium is stored. Proteins must be properly folded – have the right shape – to function properly in a cell. Within the ER (endoplasmic reticulum), there are processes that check to make sure that proteins are made and folded correctly. If the proteins are not correct or there is a stressor that causes too many proteins to be needed, a response pathway called the unfolded protein response kicks in. When overwhelmed, this response promotes cell death. This entire process prevents the cell from producing misfolded or altered proteins.[ref]

Studies show that high homocysteine levels cause ER stress and activate the unfolded protein response pathway, which can lead to cell death. High homocysteine can induce oxidative stress in the ER. It can also modify proteins by incorporating homocysteine instead of methionine into the proteins. This change in sulfide bond formation then causes protein misfolding.[ref]

Mitochondrial dysfunction:
Elevated homocysteine levels have been shown to cause mitochondrial dysfunction. Specifically, high homocysteine inhibits complex I-III, directly impacting the ability of mitochondria to produce ATP.[ref]

High homocysteine and chronic diseases:

High homocysteine can cause chronic health conditions by:

  • Increasing oxidative stress
  • Causing endoplasmic reticulum (ER) stress
  • Incorporation into proteins in the place of methionine

Mendelian randomization studies can be used to show a cause-and-effect relationship between a marker, such as homocysteine, and a disease. High homocysteine is causative for the following:

Conditions with causal or strong links to high homocysteine
Condition Evidence summary Likely mechanisms
Type 2 diabetes MR analyses support a causal role of higher genetically predicted homocysteine.​ ROS in pancreatic beta cells, mitochondrial dysfunction, ER stress.​
NAFLD/MAFLD Genetic MR: higher homocysteine increases odds of NAFLD.​ Hepatic oxidative stress, impaired methylation, disturbed lipid handling.​
Stroke / CVD MR shows modestly higher homocysteine increases stroke risk; endothelial injury and atherosclerosis documented.​ Endothelial damage, pro-thrombotic protein modification, oxidative stress.​
Metabolic syndrome & OA MR studies support a causal contribution to metabolic syndrome and worsening osteoarthritis.​ Systemic inflammation, altered matrix proteins, oxidative damage.​
Cataracts & Alzheimer’s Higher homocysteine increases cataract and Alzheimer’s risk; exacerbates amyloid-β toxicity.​ Protein misfolding, ER stress, mitochondrial dysfunction, neurotoxicity.​
Brain atrophy B-vitamin–mediated lowering of homocysteine slows brain atrophy in MCI.​ Vascular injury, impaired methylation, neurodegeneration.​
Depression Higher homocysteine correlates with MDD and worse cognitive scores.​ Neuroinflammation, impaired monoamine synthesis and methylation.​
Pregnancy complications High homocysteine linked to pre-eclampsia, NTDs, placental pathology, preterm birth, loss.​ Endothelial dysfunction, thrombosis, impaired methylation in placenta/fetus.​

Let’s take a look at the details on each of these:

Diabetes:
Type 2 diabetes is associated with higher homocysteine levels, and genetic Mendelian randomization studies show that higher homocysteine is a causative factor. Researchers believe this is due to increased ROS (increased oxidative stress) in the pancreatic beta cells.[ref]

Related article: Type 2 Diabetes Genes

Fatty liver disease:
High homocysteine levels are associated with NAFLD (fatty liver disease, MAFLD). A recent analysis using Mendelian randomization showed that genetically predicted homocysteine levels increased the odds of NAFLD.[ref]

Related article: NAFLD genes

Cardiovascular disease:
To answer the question of whether “a modestly elevated homocysteine level is causally associated with an increased risk of cardiovascular disease”, researchers again used huge genetic data sets and Mendelian randomization to determine causality. Modestly higher homocysteine, as predicted by genetics, was associated with an increased risk of stroke.[ref] High homocysteine levels can damage the endothelium (lining of the blood vessels) and cause hardening of the arteries.[ref]

Related article: Heart disease genes

Chronic diseases:
Similarly, MR studies have shown that high homocysteine can cause metabolic syndrome, worsen osteoarthritis, increase the risk of cataracts, and increase the risk of Alzheimer’s disease. [ref][ref][ref][ref]

Brain atrophy:
High homocysteine is associated with brain atrophy and cognitive decline in aging. Lowering homocysteine levels by supplementing with B vitamins has been shown to reduce the rate of brain atrophy in elderly people with mild cognitive impairment.[ref] Researchers have found that high homocysteine exacerbates amyloid-beta-induced cell death in the brain.[ref]

Osteoporosis:
Researchers think the connection between high homocysteine and osteoporosis could be due to dysregulation of the transsulfuration pathway rather than a problem with the remethylation of homocysteine. The dysregulation of the transsulfuration pathway could result in higher homocysteine levels and lower cysteine and taurine levels.[ref]

Related article: Osteoporosis

Depression:
Higher levels of homocysteine are found in people with major depressive disorder, on average. The homocysteine levels also correlate with negative cognitive scores (e.g. brain fog) in depression patients. [ref]

Related articles: Depression and Inflammation & Depression and mitochondrial dysfunction

Pre-eclampsia and pregnancy complications:
Pregnant women with high homocysteine levels are at a much greater risk of pre-eclampsia, which may be due to the changes in the endothelial cells from hyperhomocysteinemia. High homocysteine levels are also associated with neural tube defects, placental abruption, pre-term birth, and recurrent pregnancy loss.[ref]

How is high homocysteine defined?

Normal: The range of normal homocysteine levels is defined in some research studies as 5-15 μmol/L. Others use 13μmol/L as the upper limit of normal.

High homocysteine:
Hyperhomocysteinemia (high homocysteine) is usually defined as greater than 15 μmol/L. Some research studies break high homocysteine into three categories:  mild (15 to 30 µmol/L), moderate (30 to 100 µmol/L), and severe (greater than 100 µmol/L). [ref][ref]

Low homocysteine:
This is a less common and less studied condition, characterized by homocysteine levels under 5 mmol/L. Low homocysteine could indicate an impaired ability to produce glutathione.[ref] People with Down syndrome may have three copies of the CBS mutation and subsequently very low homocysteine. Timing of the test, as well as a high-protein meal, may also cause temporary drops in homocysteine levels in test results.

What is the optimal level for homocysteine?
Estimates of all-cause mortality seem to start rising around homocysteine levels of 9-10 μmol/L, but there is likely a lot of individual variation in whether homocysteine below the upper limit of 13-15 μmol/L is worrisome. There is a clear increase in mortality rates above 15 μmol/L.

Screenshot from a study on homocysteine and all-cause mortality PMC9578792

Circadian rhythm of homocysteine:

A study in healthy adults showed that homocysteine levels vary by about 3μmol/L over the course of a day. The peak is around midnight, and the lowest levels are around 2 pm. The study also showed that eating a meal with a lot of protein (containing the amino acid methionine) increases homocysteine levels a little bit over the next 8 hours.[ref]

Two important takeaways here:

  • If you are tracking your homocysteine levels with blood tests, test at the same time of day. An afternoon test is likely to give you a test result that is several points lower than an early morning test.
  • Similarly, eating a high-protein meal several hours before the test will raise homocysteine levels a little bit.
Circadian changes in homocysteine and impact of sleep timing. CC image, open-access article worth reading. PMC520826

What raises homocysteine levels?

Homocysteine levels can be high for a number of reasons:[ref][ref]

  1. Insufficient folate and B12 (exacerbated by variants in MTHFR, MTR – see genotype report below)
  2. Not enough B6 (CBS pathway, B6 – see genotype report)
  3. More methionine than the body can handle
  4. Renal insufficiency (kidney disease) or alcoholism

Genetic mutations in the CBS gene can cause rare cases of hyperhomocysteinemia. Children with rare mutations in the CBS or MTR genes can have neural tube defects, early atherosclerosis, or neurological effects.[ref]

Related article: MTHFR and the methylation cycle

Sex, age, and smoking:
Men tend to have higher homocysteine levels than women, and homocysteine levels in both sexes tend to increase slightly with age. Smoking is also associated with higher homocysteine levels.[ref][ref][ref]

Folate and B12 status:
In general, higher folate and vitamin B12 levels are associated with lower homocysteine levels.[ref] This association holds true with aging.[ref]

Amount of methionine in the diet:
Methionine is an essential amino acid found in protein-rich foods. While we need methionine and protein in the diet, one way to increase homocysteine is to significantly increase dietary methionine without a concomitant increase in choline, B12, or folate.[ref]

Timing of testing:
Homocysteine levels are lowest in the first hour after a meal, so if you test your homocysteine level after eating, it will likely be different than what a fasting blood test will show.[ref]

Down syndrome, CBS, and low homocysteine:

People with Down syndrome usually have very low homocysteine levels due to the extra copy of chromosome 21, which causes an extra copy of the CBS gene. The extra CBS enzyme causes homocysteine to be lost through the transsulfuration pathway.[ref]

The gut microbiome and homocysteine:

A number of recent studies have noted that high homocysteine levels go together with changes to the gut microbiome.

Folate and B12 from the microbiome:
One connection is that the gut microbiome supplies part of our daily requirement for folate and vitamin B12, both of which are important in the methylation cycle and the regeneration of homocysteine to methionine. Conditions that drastically alter the gut microbiome, such as inflammatory bowel disease, are associated with very high levels of homocysteine. [ref]

Feedback loop:
High levels of homocysteine increase inflammatory cytokines. It’s a two-way street in IBD, with the gut microbiome changes potentially causing high homocysteine, but then high homocysteine will increase the inflammation in the gut.[ref]

Gastrointestinal production of homocysteine:

Gut microbes that produce folate:
The amount of folate produced by the gut microbiome is on a similar scale to what we get from food, so it is a significant source of folate for most people. Animal studies show that folate from gut bacteria is absorbed into the body.

Several lactic acid species produce folate, including Lactococcus lactisStreptococcus thermophilus, and Lactobacillus plantarum. Bifidobacterium animalis, B. adolescentis, and B. pseudocatenulatum also produce folate. Interestingly, microbes can synthesize the active methylfolate form.[ref][ref][ref]


Homocysteine Genotype report:

MTHFR gene: encodes the enzyme needed for turning dietary folate into methylfolate, which is used as a methyl donor to remethylate homocysteine to methionine.

Check your genetic data for rs1801133 C677T (23andMe v4, v5; AncestryDNA):

  • G/G: typical *
  • A/G: one copy of MTHFR C677T allele, enzyme function decreased by 40%;
  • A/A: two copies of MTHFR C677T, enzyme function decreased by 70 – 80%; higher homocysteine levels, especially if folate is lacking in the diet[ref][ref][ref]

Members: Your genotype for rs1801133 is .

NOX4 gene: encodes an enzyme that increases the formation of ROS (reactive oxygen species). Knocking out NOX4 in mice causes lower homocysteine levels and lower cysteine and glutathione levels. Instead, the homocysteine is pushed through the betaine-dependent methylation pathway to be remethylated.[ref]

Check your genetic data for rs11018628 (23andMe v4, v5; AncestryDNA):

  • T/T: typical
  • C/T: decreased homocysteine, decreased stroke risk
  • C/C: decreased homocysteine, decreased stroke risk[ref][ref] possibly lower glutathione levels

Members: Your genotype for rs11018628 is .

MTR gene: encodes methionine synthase, an enzyme that utilizes vitamin B12 in the methionine cycle and thus needs plenty of available methylB12

Check your genetic data for rs1805087 A2756G (23andMe v4, v5; AncestryDNA):

  • A/A: typical
  • A/G: increased enzyme activity
  • G/G: increased enzyme activity[ref], increased risk of cognitive impairment due to higher homocysteine[ref]

Members: Your genotype for rs1805087 is .

Check your genetic data for rs2275565 (23andMe v4, v5; AncestryDNA):

  • T/T: associated with higher homocysteine levels[ref]
  • G/T: associated with higher homocysteine levels
  • G/G: typical

Members: Your genotype for rs2275565 is .

MTRR gene: Methionine synthase reductase (MTRR) encodes the enzyme that regenerates vitamin B12 (methylcobalamin) for use by MTR in the methionine cycle.

Check your genetic data for rs1801394 A66G (23andMe v4, v5; AncestryDNA):

  • A/A: typical
  • A/G: somewhat decreased enzyme efficiency; somewhat increased homocysteine levels, especially if riboflavin is low
  • G/G: decreased enzyme efficiency [ref][ref][ref][ref][ref] somewhat increased homocysteine levels, especially if riboflavin is low[ref]

Members: Your genotype for rs1801394 is .

CBS gene: encodes the cystathionine beta-synthase enzyme, which acts with vitamin B6 in the transsulfuration pathway to remove homocysteine (forming cysteine, a building block of glutathione)

Check your genetic data for rs5742905 (23andMe v4 only):

  • G/G: risk of increased homocysteine, responsive to vitamin B6[ref][ref]
  • A/G: risk of increased homocysteine, responsive to vitamin B6
  • A/A: typical

Members: Your genotype for rs5742905 is .


PEMT gene: encodes phosphatidylethanolamine N-methyltransferase, an essential enzyme for the production of choline in the body. Using SAMe as a methyl donor, PEMT catalyzes the reaction to triple methylate PE to form phosphatidylcholine.[ref]

Check your genetic data for rs7946 V175M (23andMe v4, v5; AncestryDNA)

  • C/C: typical PEMT activity (most common genotype worldwide)
  • C/T: somewhat decreased PEMT enzyme activity
  • T/T: decreased PEMT enzyme activity[ref], homocysteine increases with low folate diet[ref]( most common genotype for Caucasian populations)

Members: Your genotype for rs7946 is .

BHMT gene:  Encodes an enzyme needed for the conversion of dietary choline to betaine, which can be used to remethylate homocysteine into methionine.

Check your genetic data for rs3733890 R239Q G716A (23andMe v4, v5; AncestryDNA):

  • A/A: reduced BHMT[ref][ref] reduced conversion of choline to betaine[ref] increased risk of early-onset heart disease with poor diet[ref]
  • A/G: reduced BHMT, reduced conversion of choline to betaine, increased risk of early-onset heart disease with poor diet
  • G/G: typical

Members: Your genotype for rs3733890 is .

 

PON1 gene: encodes paraoxonase, an enzyme that breaks down homocysteine-thiolactone, organophosphorus compounds (insecticides, nerve gas), and plays a role in protecting LDL cholesterol from oxidation.[ref] Higher PON1 activity may help to decrease homocysteine-thiolactone levels and minimize the damage to endothelial cells and to the brain.

Note that not all studies agree on the link between PON1 and heart disease, so I’ve gone with what the meta-analysis shows.

Check your genetic data for rs662 Q192R (23andMe v4, v5; AncestryDNA):

  • T/T: typical variant (higher PON1 activity, denoted as Q)
  • C/T: typical risk
  • C/C: increased risk of heart disease(denoted as R in studies)[ref][ref][ref][ref]

Members: Your genotype for rs662 is .


Lifehacks: Natural Ways to Lower Homocysteine Levels

The only way to know your homocysteine level is to get it tested. It’s an inexpensive test, and you can order it yourself in the US if you can’t get it done at your doctor’s office.

If your homocysteine level is high, the following dietary changes and supplements may help.  As always, talk with your doctor if you have any medical questions or concerns about interactions between supplements and medications.

 

Practical ways to lower homocysteine
Strategy Mechanism Works best when…
Increase folate-rich foods Provides methyl groups via the folate cycle, lowering homocysteine.​ Low folate intake; MTHFR C677T carriers; PEMT rs7946 TT on low-folate diets.​
Optimize B12, riboflavin Cofactor for MTR remethylation of homocysteine.​ Low B12 status, vegetarian/vegan diets, MTR/MTRR variants, B2 variants.​
Ensure adequate B6 Cofactor for CBS in transsulfuration to cysteine/glutathione.​ Transsulfuration bottlenecks; CBS variants; high oxidative stress load.​
Support choline/betaine Feeds the BHMT pathway to remethylate homocysteine.​ BHMT/PEMT variants, high methionine intake, fatty liver risk.​
Address kidney and vascular health Kidneys clear homocysteine/thiolactone; endothelium is a key target tissue.​ Renal insufficiency, CVD risk, PON1 variants, inflammatory conditions.​
Support gut microbiome Microbes supply folate/B12 and can make methylfolate.​ IBD, dysbiosis, low-folate diets; need extra folate/B12 support from microbiota.​
Taurine, NAC, or Creatine Shown in studies to lower homocysteine. Options, choose which works best for you

Diet changes for lowering homocysteine:

Folate-rich foods:

Increasing dietary folate by eating more folate-rich foods has been shown in clinical trials to lower homocysteine levels.[ref][ref][ref]

For example, one clinical trial found that adding more folate to the diet by increasing the number of servings of vegetables eaten each day reduced homocysteine levels by 13%.[ref]

Eating more folate-rich whole foods, such as dark leafy green vegetables, also has the benefit of increasing other vitamins and antioxidants.

Who will this work best for?
If you have the PEMT rs7946 TT genotype (above), a low-folate diet is more likely to raise your homocysteine levels. If you have high homocysteine with this genotype, you could focus on increasing dietary folate or supplementing with methylfolate.

For people with the MTHFR C677T homozygous variant (AA genotype above), adding more folate-rich foods significantly lowered homocysteine levels.[ref]

What if you get enough folate? Studies show a clear benefit for lowering homocysteine by raising folate to adequate levels, but there’s no additional benefit seen from adding more folate for people who already get plenty of folate.[ref][ref]

Decreasing animal protein (maybe):
Higher levels of dietary methionine, such as from a diet high in animal protein, can increase homocysteine levels.[ref]

However, a high-protein diet usually contains more vitamin B12, vitamin B6, betaine, and folate, which may offset the increase in methionine in real life.[ref] In laboratory settings, people who eat foods high in methionine alone show an increase in homocysteine, but this is attenuated when the increased methionine is consumed along with other amino acids.[ref]

Natural vitamins and supplements for decreasing homocysteine:

Folate:
Dozens of studies and placebo-controlled clinical trials show that increasing folate can lower high homocysteine levels. Clinical trials use either folic acid (a synthetic formula that is converted into folate) or the active form of folate, methylfolate. Effective doses appear to start at 100 – 200 mcg/day.[ref][ref]

The RDA for folate from food is 400 mcg/day. For people with normal homocysteine levels (e.g., between 7-8), adding folic acid doesn’t statistically lower their homocysteine levels.[ref] When researchers compared adding more folate-rich foods (+350 mcg/day of folate) with a folic acid supplement (250 mcg/day of folic acid), they found that both groups had similar decreases in homocysteine.[ref]

Who will this work best for?
Anyone who is low in folate (and high in homocysteine) is likely to benefit from a folate supplement. People with the MTHFR C677T homozygous (AA genotype) have been shown to benefit most from folate to lower homocysteine. [ref]

Related article: Read about DHFR variants and folic acid

Vitamin B12: 
Supplemental B12 may reduce high homocysteine levels in people who are deficient in intake. There are several types of B12 available as supplements, including methylcobalamin (methylB12), adenosylcobalamin, or hydroxycobalamin.

People with slow COMT function may want to avoid supplementing with high doses of methyl donor supplements, such as methylB12 (methylcobalamin) or methylfolate. Read more about COMT and supplement interactions here.

🚩 Heads up: 🧬 COMT interaction
Your genotype for COMT rs4680 is , which means your connected data file indicates slow COMT function. Some people with slow COMT report irritability or mood changes when taking methyl donors or COMT inhibitors. Read the full article on COMT here.

Who might this work best for?
While getting enough vitamin B12 is important for everyone, it is probably more important for people with the MTR or MTRR variants, which directly use vitamin B12.

Taurine:
In a study of healthy women aged 33 -54, taurine supplementation lowered homocysteine levels. The average initial homocysteine was 8.5 umol/L. After 4 weeks of taking 3g of taurine per day, homocysteine decreased to an average of 7.6 umol/L.[ref]

Who might this work best for?
While taurine may help everyone a little bit, animal studies show that taurine is effective in lowering homocysteine levels when BHMT is impaired.[ref]

Related article: Taurine: Research on healthspan and supplements 

N-Acetylcysteine (NAC):
NAC is a supplemental form of cysteine. A clinical trial involving 82 adults found that supplemental NAC (1.8g/day for 4 weeks) lowered plasma homocysteine levels.[ref]

Who might this work best for?
The clinical trial did not separate participants by genotype, so NAC may work for most people with high homocysteine. Animal studies suggest that NAC may be more important for NOX4 variants. In NOX4 knockout mice, cysteine helped protect the liver from acetaminophen injury.[ref]

Vitamin B6, pyroxidine:
Vitamin B6 is an essential cofactor in the transulfuration pathway with the CBS enzyme, which converts homocysteine to cysteine (and then to glutathione). A clinical trial of folate plus vitamin B6 showed that the combination was effective in lowering homocysteine levels.[ref]

Who might this work best for?
If you have high levels of inflammation and oxidative stress, you may need more glutathione to act as an intracellular antioxidant. If you don’t get enough vitamin B6 in your diet, you may want to try a vitamin B6 supplement. The active form of B6 is called pyridoxal 5′-phosphate or P5P.

Related article: Vitamin B6, genetics, safety

Vitamin B2, riboflavin:
A clinical trial found that riboflavin (vitamin B2) was effective in reducing plasma homocysteine levels.[ref]

Who might this work for?
Riboflavin may be particularly helpful for people with the MTRR G allele.[ref] Additionally, studies show that riboflavin is particularly effective in people who are homozygous for MTHFR C677T (AA genotype).[ref]

Related article: MTR, MTRR and more about B12

The B vitamins together: B-complex for the win
Many studies show that a combination of folate, riboflavin, and/or vitamin B6 is very effective for lowering homocysteine.[ref][ref]

Betaine or choline:
Methyl groups to remethylate homocysteine can also be supplied by betaine (also called TMG) or choline in the diet.[ref] Beets are a good source of betaine, and eggs are rich in choline.

Creatine:
The largest use of methyl groups is in the synthesis of creatine. Supplemental creatine can help to lower homocysteine levels in healthy people with good kidney function.[ref][ref][ref]

Related article: Creatine: Boosting muscles and cognitive function

Who might this work for?
Many of the studies on creatine for lowering homocysteine levels have been done in healthy people who were also lifting weights. If you don’t have any reason not to take it, such as kidney disease, creatine may be a good option for people with slow COMT variants who want to avoid methylfolate and methylB12 supplements. As a powder, creatine is inexpensive and easy to mix into any beverage (mild taste).

Antioxidants, pomegranate:
Low PON1 is associated with higher homocysteine. Antioxidant vitamins, C and E, or pomegranate juice, can increase PON1 levels.[ref] For people with the PON1 variant, you may want to consider how many antioxidant-rich foods you eat each day.

Probiotics for B vitamins:
The connection between the gut microbiome produced folate and homocysteine is intriguing. Unfortunately, there are no placebo-controlled trials of probiotics for homocysteine reduction. However, if you have gut dysbiosis and high homocysteine levels, consider trying a probiotic containing  Lactobacillus plantarum,  Bifidobacterium animalis, or B. adolescentis. Yogurt may also help to provide these bacteria.

Keeping track:

If you are trying to lower homocysteine levels with supplements or dietary changes, I would suggest getting your homocysteine levels tested first to know your baseline. Then test again in 4-6 weeks to see if your interventions are making a difference. Keep track of what you’re taking, track your lab tests, and see if the interventions have a positive effect.

Recap of your genes:


Related  articles:

DHFR and MTHFR: Folic Acid Metabolism

Creatine: Boosting Muscles and Increasing Brain Power

misspellings: transulfation, transulfuration, sulfur, sulpher, homocisteine, homocystein, methelation, MTHR, mutation </span


References:

Aarsand, A. K., and S. M. Carlsen. “Folate Administration Reduces Circulating Homocysteine Levels in NIDDM Patients on Long-Term Metformin Treatment.” Journal of Internal Medicine, vol. 244, no. 2, Aug. 1998, pp. 169–74. PubMed, https://doi.org/10.1046/j.1365-2796.1998.00361.x.
Agostini, Deborah, et al. “Homocysteine, Nutrition, and Gut Microbiota: A Comprehensive Review of Current Evidence and Insights.” Nutrients, vol. 17, no. 8, Apr. 2025, p. 1325. PubMed Central, https://doi.org/10.3390/nu17081325.
Ahn, Chang Soon. “Effect of Taurine Supplementation on Plasma Homocysteine Levels of the Middle-Aged Korean Women.” Advances in Experimental Medicine and Biology, vol. 643, 2009, pp. 415–22. PubMed, https://doi.org/10.1007/978-0-387-75681-3_43.
Ai, Yanbiao, et al. “Homocysteine Induces Hepatic Steatosis Involving ER Stress Response in High Methionine Diet-Fed Mice.” Nutrients, vol. 9, no. 4, Apr. 2017, p. 346. PubMed Central, https://doi.org/10.3390/nu9040346.
Anfinsen, Åslaug Matre, et al. “Exploratory Analyses on the Effect of Time since Last Meal on Concentrations of Amino Acids, Lipids, One-Carbon Metabolites, and Vitamins in the Hordaland Health Study.” European Journal of Nutrition, vol. 62, no. 7, Oct. 2023, pp. 3079–95. Springer Link, https://doi.org/10.1007/s00394-023-03211-y.
Appel, L. J., et al. “Effect of Dietary Patterns on Serum Homocysteine: Results of a Randomized, Controlled Feeding Study.” Circulation, vol. 102, no. 8, Aug. 2000, pp. 852–57. PubMed, https://doi.org/10.1161/01.cir.102.8.852.
Baranska, Malgorzata, et al. “Polymorphism Rs662 (Q192R) of Paraoxonase-1 and Susceptibility to Atherosclerosis of the Coronary Arteries.” Archives of Medical Science : AMS, vol. 20, no. 4, Aug. 2024, pp. 1328–33. PubMed Central, https://doi.org/10.5114/aoms/192273.
Bereket-Yücel, S. “Creatine Supplementation Alters Homocysteine Level in Resistance Trained Men.” The Journal of Sports Medicine and Physical Fitness, vol. 55, no. 4, Apr. 2015, pp. 313–19.
Berry, Thomas M., and Ahmed A. Moustafa. “Osteoporosis and the Effect of Dysregulation of the Transsulfuration Pathway via Taurine on Intracellular Calcium Homeostasis, Vitamin D Absorption and Vitamin K Absorption.” Clinical Nutrition ESPEN, vol. 43, June 2021, pp. 191–96. ScienceDirect, https://doi.org/10.1016/j.clnesp.2021.02.023.
Bharathselvi, Muthuvel, Sayantan Biswas, et al. “Homocysteine & Its Metabolite Homocysteine-Thiolactone & Deficiency of Copper in Patients with Age Related Macular Degeneration – A Pilot Study.” The Indian Journal of Medical Research, vol. 143, no. 6, June 2016, pp. 756–62. PubMed, https://doi.org/10.4103/0971-5916.192026.
Bharathselvi, Muthuvel, Jyothirmay Biswas, et al. “Increased Homocysteine, Homocysteine-Thiolactone, Protein Homocysteinylation and Oxidative Stress in the Circulation of Patients with Eales’ Disease.” Annals of Clinical Biochemistry, vol. 50, no. Pt 4, July 2013, pp. 330–38. PubMed, https://doi.org/10.1177/0004563213492146.
Brouwer, I. A., et al. “Dietary Folate from Vegetables and Citrus Fruit Decreases Plasma Homocysteine Concentrations in Humans in a Dietary Controlled Trial.” The Journal of Nutrition, vol. 129, no. 6, June 1999, pp. 1135–39. PubMed, https://doi.org/10.1093/jn/129.6.1135.
Cao, Lirong, et al. “Association of Neural Tube Defects with Gene Polymorphisms in One-Carbon Metabolic Pathway.” Child’s Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery, vol. 34, no. 2, Feb. 2018, pp. 277–84. PubMed, https://doi.org/10.1007/s00381-017-3558-z.
Carey, Ashley, et al. “Homocysteine Potentiates Amyloid Β‐induced Death Receptor 4‐ and 5‐mediated Cerebral Endothelial Cell Apoptosis, Blood Brain Barrier Dysfunction and Angiogenic Impairment.” Aging Cell, vol. 23, no. 5, May 2024, p. e14106. DOI.org (Crossref), https://doi.org/10.1111/acel.14106.
CBS Gene: MedlinePlus Genetics. https://medlineplus.gov/genetics/gene/cbs/. Accessed 24 Feb. 2026.
Cheng, Chak Kwong, et al. “A GLP-1 Analog Lowers ER Stress and Enhances Protein Folding to Ameliorate Homocysteine-Induced Endothelial Dysfunction.” Acta Pharmacologica Sinica, vol. 42, no. 10, Oct. 2021, pp. 1598–609. PubMed Central, https://doi.org/10.1038/s41401-020-00589-x.
Cheng, Yating, et al. “Circulating Homocysteine and Folate Concentrations and Risk of Type 2 Diabetes: A Retrospective Observational Study in Chinese Adults and a Mendelian Randomization Analysis.” Frontiers in Cardiovascular Medicine, vol. 9, Nov. 2022. Frontiers, https://doi.org/10.3389/fcvm.2022.978998.
Clément, Arthur, et al. “MTHFR SNPs (Methyl Tetrahydrofolate Reductase, Single Nucleotide Polymorphisms) C677T and A1298C Prevalence and Serum Homocysteine Levels in >2100 Hypofertile Caucasian Male Patients.” Biomolecules, vol. 12, no. 8, Aug. 2022, p. 1086. PubMed Central, https://doi.org/10.3390/biom12081086.
Dahabreh, Issa J., et al. “Paraoxonase 1 Polymorphisms and Ischemic Stroke Risk: A Systematic Review and Meta-Analysis.” Genetics in Medicine: Official Journal of the American College of Medical Genetics, vol. 12, no. 10, Oct. 2010, pp. 606–15. PubMed, https://doi.org/10.1097/GIM.0b013e3181ee81c6.
den Heijer, M., et al. “Vitamin Supplementation Reduces Blood Homocysteine Levels: A Controlled Trial in Patients with Venous Thrombosis and Healthy Volunteers.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 3, Mar. 1998, pp. 356–61. PubMed, https://doi.org/10.1161/01.atv.18.3.356.
Deng, Z., et al. “Significant Association between Paraoxonase 1 Rs662 Polymorphism and Coronary Heart Disease : A Meta-Analysis in the Chinese Population.” Herz, vol. 45, no. 4, June 2020, pp. 347–55. PubMed, https://doi.org/10.1007/s00059-018-4737-8.
Engevik, Melinda A., et al. “Microbial Metabolic Capacity for Intestinal Folate Production and Modulation of Host Folate Receptors.” Frontiers in Microbiology, vol. 10, Oct. 2019. Frontiers, https://doi.org/10.3389/fmicb.2019.02305.
Finkelstein, J. D. “The Metabolism of Homocysteine: Pathways and Regulation.” European Journal of Pediatrics, 157 Suppl 2, Apr. 1998, pp. S40-44. PubMed, https://doi.org/10.1007/pl00014300.
Fuhrman, Bianca. “Regulation of Hepatic Paraoxonase-1 Expression.” Journal of Lipids, vol. 2012, 2012, p. 684010. PubMed Central, https://doi.org/10.1155/2012/684010.
Ganguly, Paul, and Sreyoshi Fatima Alam. “Role of Homocysteine in the Development of Cardiovascular Disease.” Nutrition Journal, vol. 14, Jan. 2015, p. 6. PubMed Central, https://doi.org/10.1186/1475-2891-14-6.
Ganz, Ariel B., et al. “Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism in Young Women Consuming Choline Intakes Meeting Current Recommendations.” International Journal of Molecular Sciences, vol. 18, no. 2, Jan. 2017, p. 252. PubMed Central, https://doi.org/10.3390/ijms18020252.
———. “Genetic Variation in Choline-Metabolizing Enzymes Alters Choline Metabolism in Young Women Consuming Choline Intakes Meeting Current Recommendations.” International Journal of Molecular Sciences, vol. 18, no. 2, Jan. 2017, p. 252. PubMed Central, https://doi.org/10.3390/ijms18020252.
García-Minguillán, Carlos J., et al. “Riboflavin Status Modifies the Effects of Methylenetetrahydrofolate Reductase (MTHFR) and Methionine Synthase Reductase (MTRR) Polymorphisms on Homocysteine.” Genes & Nutrition, vol. 9, no. 6, Nov. 2014, p. 435. PubMed Central, https://doi.org/10.1007/s12263-014-0435-1.
Garibotto, Giacomo, et al. “Homocysteine Exchange across Skeletal Muscle in Patients with Chronic Kidney Disease.” Physiological Reports, vol. 11, no. 6, Mar. 2023, p. e15573. PubMed Central, https://doi.org/10.14814/phy2.15573.
Gillies, Nicola A., et al. “Responsiveness of One-Carbon Metabolites to a High-Protein Diet in Older Men: Results from a 10-Wk Randomized Controlled Trial.” Nutrition (Burbank, Los Angeles County, Calif.), vol. 89, Sept. 2021, p. 111231. PubMed, https://doi.org/10.1016/j.nut.2021.111231.
Grzegorzewska, Alicja E., et al. “Paraoxonase 1 Gene Variants Concerning Cardiovascular Mortality in Conventional Cigarette Smokers and Non-Smokers Treated with Hemodialysis.” Scientific Reports, vol. 11, no. 1, Sept. 2021, p. 19467. PubMed, https://doi.org/10.1038/s41598-021-98923-8.
Hao, Ling, et al. “Folate Status and Homocysteine Response to Folic Acid Doses and Withdrawal among Young Chinese Women in a Large-Scale Randomized Double-Blind Trial12.” The American Journal of Clinical Nutrition, vol. 88, no. 2, Aug. 2008, pp. 448–57. ScienceDirect, https://doi.org/10.1093/ajcn/88.2.448.
Harmon, D. L., et al. “Methionine Synthase D919G Polymorphism Is a Significant but Modest Determinant of Circulating Homocysteine Concentrations.” Genetic Epidemiology, vol. 17, no. 4, Nov. 1999, pp. 298–309. PubMed, https://doi.org/10.1002/(SICI)1098-2272(199911)17:4%3C298::AID-GEPI5%3E3.0.CO;2-V.
Hasan, Tauheed, et al. “Disturbed Homocysteine Metabolism Is Associated with Cancer.” Experimental & Molecular Medicine, vol. 51, no. 2, Feb. 2019, p. 21. PubMed Central, https://doi.org/10.1038/s12276-019-0216-4.
He, Wei, et al. “NOX4 Rs11018628 Polymorphism Associates with a Decreased Risk and Better Short-Term Recovery of Ischemic Stroke.” Experimental and Therapeutic Medicine, vol. 16, no. 6, Dec. 2018, pp. 5258–64. PubMed Central, https://doi.org/10.3892/etm.2018.6874.
Henry, Olivia R., et al. “Suppression of Homocysteine Levels by Vitamin B12 and Folates: Age and Gender Dependency in the Jackson Heart Study.” The American Journal of the Medical Sciences, vol. 344, no. 2, Aug. 2012, pp. 110–15. PubMed Central, https://doi.org/10.1097/MAJ.0b013e31823782a5.
Hildebrandt, Wulf, et al. “Oral N-Acetylcysteine Reduces Plasma Homocysteine Concentrations Regardless of Lipid or Smoking Status.” The American Journal of Clinical Nutrition, vol. 102, no. 5, Nov. 2015, pp. 1014–24. PubMed, https://doi.org/10.3945/ajcn.114.101964.
Hong, Haofeng, et al. “Associations of Homocysteine, Folate, and Vitamin B12 with Osteoarthritis: A Mendelian Randomization Study.” Nutrients, vol. 15, no. 7, Mar. 2023, p. 1636. PubMed, https://doi.org/10.3390/nu15071636.
Hu, Qingting, et al. “Homocysteine and Alzheimer’s Disease: Evidence for a Causal Link from Mendelian Randomization.” Journal of Alzheimer’s Disease: JAD, vol. 52, no. 2, Mar. 2016, pp. 747–56. PubMed, https://doi.org/10.3233/JAD-150977.
Huang, Lu-Wen, et al. “Association of the Methylenetetrahydrofolate Reductase (MTHFR) Gene Variant C677T with Serum Homocysteine Levels and the Severity of Ischaemic Stroke: A Case–Control Study in the Southwest of China.” The Journal of International Medical Research, vol. 50, no. 2, Feb. 2022, p. 03000605221081632. PubMed Central, https://doi.org/10.1177/03000605221081632.
Huang, Xiao, et al. “MTHFR Gene and Serum Folate Interaction on Serum Homocysteine Lowering: Prospect for Precision Folic Acid Treatment.” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 3, Mar. 2018, pp. 679–85. PubMed, https://doi.org/10.1161/ATVBAHA.117.310211.
Ivanov, Alexandre, et al. “Genetic Variants in Phosphatidylethanolamine N-Methyltransferase (PEMT) and Methylenetetrahydrofolate Dehydrogenase (MTHFD1) Influence Biomarkers of Choline Metabolism When Folate Intake Is Restricted.” Journal of the American Dietetic Association, vol. 109, no. 2, Feb. 2009, pp. 313–18. PubMed Central, https://doi.org/10.1016/j.jada.2008.10.046.
Jakubowski, Hieronim. “Homocysteine Modification in Protein Structure/Function and Human Disease.” Physiological Reviews, vol. 99, no. 1, Jan. 2019, pp. 555–604. DOI.org (Crossref), https://doi.org/10.1152/physrev.00003.2018.
———. “Homocysteine Thiolactone Detoxifying Enzymes and Alzheimer’s Disease.” International Journal of Molecular Sciences, vol. 25, no. 15, July 2024, p. 8095. PubMed Central, https://doi.org/10.3390/ijms25158095.
Jørgensen, Anne, et al. “Interaction between Paraoxonase 1 Polymorphism and Prenatal Pesticide Exposure on Metabolic Markers in Children Using a Multiplex Approach.” Reproductive Toxicology (Elmsford, N.Y.), vol. 51, Jan. 2015, pp. 22–30. PubMed, https://doi.org/10.1016/j.reprotox.2014.11.005.
Jurkowska, Halina, et al. “Downregulation of Hepatic Betaine:Homocysteine Methyltransferase (BHMT) Expression in Taurine-Deficient Mice Is Reversed by Taurine Supplementation in Vivo.” Amino Acids, vol. 48, no. 3, Mar. 2016, pp. 665–76. PubMed, https://doi.org/10.1007/s00726-015-2108-9.
Koklesova, Lenka, et al. “Homocysteine Metabolism as the Target for Predictive Medical Approach, Disease Prevention, Prognosis, and Treatments Tailored to the Person.” The EPMA Journal, vol. 12, no. 4, Nov. 2021, pp. 477–505. PubMed Central, https://doi.org/10.1007/s13167-021-00263-0.
Korzun, William J. “Oral Creatine Supplements Lower Plasma Homocysteine Concentrations in Humans.” Clinical Laboratory Science: Journal of the American Society for Medical Technology, vol. 17, no. 2, 2004, pp. 102–06.
Lavie, Lena, and Peretz Lavie. “Daily Rhythms in Plasma Levels of Homocysteine.” Journal of Circadian Rhythms, vol. 2, Sept. 2004, p. 5. PubMed Central, https://doi.org/10.1186/1740-3391-2-5.
Lee, Ho-Sun, et al. “The Homocysteine and Metabolic Syndrome: A Mendelian Randomization Study.” Nutrients, vol. 13, no. 7, July 2021, p. 2440. PubMed, https://doi.org/10.3390/nu13072440.
Li, Jiao-Jiao, et al. “Homocysteine Triggers Inflammatory Responses in Macrophages through Inhibiting CSE-H2S Signaling via DNA Hypermethylation of CSE Promoter.” International Journal of Molecular Sciences, vol. 16, no. 6, June 2015, pp. 12560–77. PubMed Central, https://doi.org/10.3390/ijms160612560.
Li, Li, et al. “The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.” Nutrients, vol. 14, no. 6, Mar. 2022, p. 1224. PubMed, https://doi.org/10.3390/nu14061224.
Li, Ling, et al. “Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B12, Folate and Lipids in Patients with Alzheimer Disease.” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 4, Oct. 2008, pp. 384–90. PubMed Central, https://doi.org/10.1159/000164271.
Lin, Jonathan H., et al. “Endoplasmic Reticulum Stress in Disease Pathogenesis.” Annual Review of Pathology, vol. 3, 2008, pp. 399–425. PubMed Central, https://doi.org/10.1146/annurev.pathmechdis.3.121806.151434.
Lisboa, Jéssica Vanessa de Carvalho, et al. “Food Intervention with Folate Reduces TNF-α and Interleukin Levels in Overweight and Obese Women with the MTHFR C677T Polymorphism: A Randomized Trial.” Nutrients, vol. 12, no. 2, Jan. 2020, p. 361. PubMed, https://doi.org/10.3390/nu12020361.
Lu, Jingtong, et al. “Association of Serum Homocysteine with Cardiovascular and All-Cause Mortality in Adults with Diabetes: A Prospective Cohort Study.” Oxidative Medicine and Cellular Longevity, vol. 2022, Oct. 2022, p. 2156483. PubMed Central, https://doi.org/10.1155/2022/2156483.
Luo, Jun, et al. “Association of MTHFR C667T Polymorphism, Homocysteine, and B Vitamins with Senile Cataract.” Journal of Nutritional Science and Vitaminology, vol. 69, no. 2, 2023, pp. 136–44. PubMed, https://doi.org/10.3177/jnsv.69.136.
Luo, Mei, et al. “Correlation of Homocysteine Metabolic Enzymes Gene Polymorphism and Mild Cognitive Impairment in the Xinjiang Uygur Population.” Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, vol. 21, Jan. 2015, pp. 326–32. PubMed Central, https://doi.org/10.12659/MSM.893226.
Mansoor, M. A., et al. “Plasma Total Homocysteine Response to Oral Doses of Folic Acid and Pyridoxine Hydrochloride (Vitamin B6) in Healthy Individuals. Oral Doses of Vitamin B6 Reduce Concentrations of Serum Folate.” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 59, no. 2, Apr. 1999, pp. 139–46. PubMed, https://doi.org/10.1080/00365519950185878.
Martínez, María Elena, et al. “Folate Fortification, Plasma Folate, Homocysteine and Colorectal Adenoma Recurrence.” International Journal of Cancer, vol. 119, no. 6, Sept. 2006, pp. 1440–46. PubMed, https://doi.org/10.1002/ijc.21978.
Moretti, Rita, et al. “Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease.” International Journal of Molecular Sciences, vol. 22, no. 4, Feb. 2021, p. 2051. PubMed Central, https://doi.org/10.3390/ijms22042051.
Moretti, Rita, and Paola Caruso. “The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice.” International Journal of Molecular Sciences, vol. 20, no. 1, Jan. 2019, p. 231. PubMed Central, https://doi.org/10.3390/ijms20010231.
Pardini, Barbara, et al. “MTHFR and MTRR Genotype and Haplotype Analysis and Colorectal Cancer Susceptibility in a Case-Control Study from the Czech Republic.” Mutation Research, vol. 721, no. 1, Mar. 2011, pp. 74–80. PubMed, https://doi.org/10.1016/j.mrgentox.2010.12.008.
Pare, Guillaumé, et al. “Novel Associations of CPS1, MUT, NOX4 and DPEP1 with Plasma Homocysteine in a Healthy Population: A Genome Wide Evaluation of 13,974 Participants in the Women’s Genome Health Study.” Circulation. Cardiovascular Genetics, vol. 2, no. 2, Jan. 2009, pp. 142–50. PubMed Central, https://doi.org/10.1161/CIRCGENETICS.108.829804.
Perła-Kaján, Joanna, et al. “Paraoxonase 1 Q192R Genotype and Activity Affect Homocysteine Thiolactone Levels in Humans.” FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, May 2018, p. fj201800346R. PubMed, https://doi.org/10.1096/fj.201800346R.
Pizzorno, Joseph. “Homocysteine: Friend or Foe?” Integrative Medicine: A Clinician’s Journal, vol. 13, no. 4, Aug. 2014, pp. 8–14. PubMed Central, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566450/.
Pogribna, Marta, et al. “Homocysteine Metabolism in Children with Down Syndrome: In Vitro Modulation.” American Journal of Human Genetics, vol. 69, no. 1, July 2001, pp. 88–95. PubMed Central, https://doi.org/10.1086/321262.
Ponce-Ruiz, N., et al. “PON1 Status and Homocysteine Levels as Potential Biomarkers for Cardiovascular Disease.” Experimental Gerontology, vol. 140, Oct. 2020, p. 111062. ScienceDirect, https://doi.org/10.1016/j.exger.2020.111062.
Pullin, C. H., et al. “Optimization of Dietary Folate or Low-Dose Folic Acid Supplements Lower Homocysteine but Do Not Enhance Endothelial Function in Healthy Adults, Irrespective of the Methylenetetrahydrofolate Reductase (C677T) Genotype.” Journal of the American College of Cardiology, vol. 38, no. 7, Dec. 2001, pp. 1799–805. PubMed, https://doi.org/10.1016/s0735-1097(01)01668-0.
Raffield, Laura M., et al. “Genome-Wide Association Study of Homocysteine in African Americans from the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Coronary Artery Risk in Young Adults Study.” Journal of Human Genetics, vol. 63, no. 3, Mar. 2018, pp. 327–37. PubMed Central, https://doi.org/10.1038/s10038-017-0384-9.
Ray, Joel G., et al. “Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism: A Randomized Trial.” Annals of Internal Medicine, vol. 146, no. 11, June 2007, pp. 761–67. PubMed, https://doi.org/10.7326/0003-4819-146-11-200706050-00157.
Refsum, Helga, et al. “The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease1.” The Journal of Nutrition, vol. 136, no. 6, June 2006, pp. 1731S-1740S. ScienceDirect, https://doi.org/10.1093/jn/136.6.1731S.
Rossi, Maddalena, et al. “Folate Production by Probiotic Bacteria.” Nutrients, vol. 3, no. 1, Jan. 2011, pp. 118–34. PubMed Central, https://doi.org/10.3390/nu3010118.
Schalinske, Kevin L., and Anne L. Smazal. “Homocysteine Imbalance: A Pathological Metabolic Marker1.” Advances in Nutrition, vol. 3, no. 6, Nov. 2012, pp. 755–62. PubMed Central, https://doi.org/10.3945/an.112.002758.
Silaste, Marja-Leena, et al. “Plasma Homocysteine Concentration Is Decreased by Dietary Intervention.” The British Journal of Nutrition, vol. 89, no. 3, Mar. 2003, pp. 295–301. PubMed, https://doi.org/10.1079/bjn2002776.
Singh, Prakruti R., et al. “Gene Polymorphisms and Low Dietary Intake of Micronutrients in Coronary Artery Disease.” Journal of Nutrigenetics and Nutrigenomics, vol. 4, no. 4, 2011, pp. 203–09. PubMed, https://doi.org/10.1159/000330229.
Skovby, Flemming, et al. “A Revisit to the Natural History of Homocystinuria Due to Cystathionine β-Synthase Deficiency.” Molecular Genetics and Metabolism, vol. 99, no. 1, Jan. 2010, pp. 1–3. DOI.org (Crossref), https://doi.org/10.1016/j.ymgme.2009.09.009.
Smith, A. David, et al. “Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial.” PloS One, vol. 5, no. 9, Sept. 2010, p. e12244. PubMed, https://doi.org/10.1371/journal.pone.0012244.
Stead, Lori M., et al. “Is It Time to Reevaluate Methyl Balance in Humans?” The American Journal of Clinical Nutrition, vol. 83, no. 1, Jan. 2006, pp. 5–10. PubMed, https://doi.org/10.1093/ajcn/83.1.5.
Taes, Youri E. C., et al. “Creatine Supplementation Does Not Decrease Total Plasma Homocysteine in Chronic Hemodialysis Patients.” Kidney International, vol. 66, no. 6, Dec. 2004, pp. 2422–28. PubMed, https://doi.org/10.1111/j.1523-1755.2004.66019.x.
Tawfik Khattab, Amr Mohamed, et al. “The Role of PON1 and CYP2D6 Genes in Susceptibility to Organophosphorus Chronic Intoxication in Egyptian Patients.” Neurotoxicology, vol. 53, Mar. 2016, pp. 102–07. PubMed, https://doi.org/10.1016/j.neuro.2015.12.015.
Torres-Sánchez, Luisa, et al. “Para-Occupational Exposure to Pesticides, PON1 Polymorphisms and Hypothyroxinemia during the First Half of Pregnancy in Women Living in a Mexican Floricultural Area.” Environmental Health: A Global Access Science Source, vol. 18, no. 1, Apr. 2019, p. 33. PubMed, https://doi.org/10.1186/s12940-019-0470-x.
Venn, Bernard J., et al. “Dietary Counseling to Increase Natural Folate Intake: A Randomized, Placebo-Controlled Trial in Free-Living Subjects to Assess Effects on Serum Folate and Plasma Total Homocysteine.” The American Journal of Clinical Nutrition, vol. 76, no. 4, Oct. 2002, pp. 758–65. PubMed, https://doi.org/10.1093/ajcn/76.4.758.
Verhoef, Petra, et al. “Dietary Serine and Cystine Attenuate the Homocysteine-Raising Effect of Dietary Methionine: A Randomized Crossover Trial in Humans.” The American Journal of Clinical Nutrition, vol. 80, no. 3, Sept. 2004, pp. 674–79. PubMed, https://doi.org/10.1093/ajcn/80.3.674.
Verhoef, Petra, and Lisette C. P. G. M. de Groot. “Dietary Determinants of Plasma Homocysteine Concentrations.” Seminars in Vascular Medicine, vol. 5, no. 2, May 2005, pp. 110–23. PubMed, https://doi.org/10.1055/s-2005-872397.
Wang, Ping, et al. “Association of MTRR A66G Polymorphism with Cancer Susceptibility: Evidence from 85 Studies.” Journal of Cancer, vol. 8, no. 2, 2017, pp. 266–77. PubMed, https://doi.org/10.7150/jca.17379.
Weiner, Alexandra S., et al. “Methylenetetrahydrofolate Reductase C677T and Methionine Synthase A2756G Polymorphisms Influence on Leukocyte Genomic DNA Methylation Level.” Gene, vol. 533, no. 1, Jan. 2014, pp. 168–72. PubMed, https://doi.org/10.1016/j.gene.2013.09.098.
Xiao, Yunjun, et al. “Dietary Protein and Plasma Total Homocysteine, Cysteine Concentrations in Coronary Angiographic Subjects.” Nutrition Journal, vol. 12, Nov. 2013, p. 144. PubMed Central, https://doi.org/10.1186/1475-2891-12-144.
Xu, Chen-Chen, et al. “Serum Homocysteine Showed Potential Association with Cognition and Abnormal Gut Microbiome in Major Depressive Disorder.” World Journal of Psychiatry, vol. 15, no. 3, Mar. 2025, p. 102567. PubMed Central, https://doi.org/10.5498/wjp.v15.i3.102567.
Xu, Weihai, et al. “Association between Methionine Synthase Reductase A66G Polymorphism and Male Infertility: A Meta-Analysis.” Critical Reviews in Eukaryotic Gene Expression, vol. 27, no. 1, 2017, pp. 37–46. PubMed, https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017018680.
Yang, Boyi, et al. “Associations of MTHFR C677T and MTRR A66G Gene Polymorphisms with Metabolic Syndrome: A Case-Control Study in Northern China.” International Journal of Molecular Sciences, vol. 15, no. 12, Nov. 2014, pp. 21687–702. PubMed Central, https://doi.org/10.3390/ijms151221687.
Yang, Qin, and Guo-Wei He. “Imbalance of Homocysteine and H2S: Significance, Mechanisms, and Therapeutic Promise in Vascular Injury.” Oxidative Medicine and Cellular Longevity, vol. 2019, Nov. 2019, p. 7629673. PubMed Central, https://doi.org/10.1155/2019/7629673.
Yang, Quanhe, et al. “Prospective Study of Methylenetetrahydrofolate Reductase (MTHFR) Variant C677T and Risk of All-Cause and Cardiovascular Disease Mortality among 6000 US Adults.” The American Journal of Clinical Nutrition, vol. 95, no. 5, May 2012, pp. 1245–53. PubMed, https://doi.org/10.3945/ajcn.111.022384.
Yuan, Shuai, Amy M. Mason, et al. “Homocysteine, B Vitamins, and Cardiovascular Disease: A Mendelian Randomization Study.” BMC Medicine, vol. 19, no. 1, Apr. 2021, p. 97. PubMed, https://doi.org/10.1186/s12916-021-01977-8.
Yuan, Shuai, Jie Chen, et al. “Homocysteine, Folate, and Nonalcoholic Fatty Liver Disease: A Systematic Review with Meta-Analysis and Mendelian Randomization Investigation.” The American Journal of Clinical Nutrition, vol. 116, no. 6, Dec. 2022, pp. 1595–609. PubMed, https://doi.org/10.1093/ajcn/nqac285.
Zappacosta, Bruno, et al. “Homocysteine Lowering by Folate-Rich Diet or Pharmacological Supplementations in Subjects with Moderate Hyperhomocysteinemia.” Nutrients, vol. 5, no. 5, May 2013, pp. 1531–43. PubMed, https://doi.org/10.3390/nu5051531.
Zeng, Rui, et al. “The Effect of Folate Fortification on Folic Acid-Based Homocysteine-Lowering Intervention and Stroke Risk: A Meta-Analysis.” Public Health Nutrition, vol. 18, no. 8, June 2015, pp. 1514–21. PubMed, https://doi.org/10.1017/S1368980014002134.
Zhang, Xiaofeng, et al. “Paraoxonase Activity and Genetic Polymorphisms in Northern Han Chinese Workers Exposed to Organophosphate Pesticides.” Experimental Biology and Medicine (Maywood, N.J.), vol. 239, no. 2, Feb. 2014, pp. 232–39. PubMed, https://doi.org/10.1177/1535370213513983.

About the Author:
Debbie Moon is a biologist, engineer, author, and the founder of Genetic Lifehacks where she has helped thousands of members understand how to apply genetics to their diet, lifestyle, and health decisions. With more than 10 years of experience translating complex genetic research into practical health strategies, Debbie holds a BS in engineering from Colorado School of Mines and an MSc in biological sciences from Clemson University. She combines an engineering mindset with a biological systems approach to explain how genetic differences impact your optimal health.